IDEXX Laboratories, Inc. - 2004 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: IDEXX Laboratories, Inc.
Reporting Period: Fiscal Year Ended December 31, 2004
Business Overview: IDEXX develops, manufactures, and distributes diagnostic products and services for the veterinary, food, and water testing markets. Operations are organized into three segments: Companion Animal Group (CAG), Water, and Food Diagnostics Group (FDG). The company is headquartered in Westbrook, Maine, and operates globally.
Key Financial Metrics (2004)
| Metric | 2004 Value | 2003 Value |
|---|---|---|
| Total Revenue | $549.2 million | $476.0 million |
| Gross Profit | $279.0 million | $230.3 million |
| Gross Margin | 50.8% | 48.4% |
| Operating Income | $108.0 million | $80.4 million |
| Net Income | $78.3 million | $57.1 million |
| Diluted EPS | $2.19 | $1.59 |
| Cash & Investments | $157.0 million | $255.8 million |
| Working Capital | $201.6 million | $270.2 million |
| Total Debt | $1.8 million | $0.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 15% ($73.2 million) driven by growth in all three segments. CAG revenue grew 17%, Water grew 13%, and FDG grew 6%.
- Profitability: Operating income increased 34% to $108.0 million. Gross margin expanded 240 basis points to 50.8%, aided by productivity improvements and favorable currency impacts.
- Acquisitions: The company completed four significant acquisitions in 2004, including Vet Med Lab (Germany) for ~$31.3 million and Dr. Bommeli AG (Switzerland) for ~$15.8 million, expanding its laboratory and production animal diagnostics footprint.
- Stock Repurchases: IDEXX repurchased 2.4 million shares for $128.8 million during the year, reducing the share count.
- Segment Performance:
- CAG: Driven by increased laboratory services volume and instrument consumables sales.
- Water: Growth supported by volume and favorable currency, though competitive pressures persist.
- FDG: Growth led by production animal diagnostics and currency effects, offset by lower dairy testing sales.
Guidance, Outlook, and Risks
- 2005 Outlook: Management expects continued growth in CAG laboratory services (incremental $20-25 million from Vet Med Lab) and FDG (driven by BSE testing in Europe and Bommeli integration). Pharmaceutical growth is expected to slow in 2005 due to the lack of new launches.
- Accounting Changes: Effective July 1, 2005, the company will adopt SFAS No. 123(R), requiring the expensing of stock-based compensation. This is estimated to result in approximately $8.0 million in pre-tax expense for 2005.
- Key Risks:
- Supply Chain: Reliance on single-source suppliers for critical components (e.g., VetTest slides from Ortho, LaserCyte components). The company has a minimum purchase commitment of $131.8 million for slides through 2010.
- Regulatory: Products are subject to strict regulation by USDA, FDA, and EPA. Failure to maintain approvals could halt sales.
- Competition: Intense competition in veterinary diagnostics and water testing, with potential for price erosion.
- Inventory: Significant inventory levels ($11.9 million) associated with the LaserCyte hematology instrument carry obsolescence risk if product design changes.
Investor Verification Checklist
- Acquisition Integration: Verify the timeline and cost of integrating Vet Med Lab and Dr. Bommeli AG to ensure projected synergies are realized.
- Stock-Based Compensation Impact: Monitor the actual expense impact of SFAS 123(R) adoption in 2005 against the $8.0 million estimate.
- Supply Agreement Compliance: Confirm that sales volumes for VetTest slides meet the $131.8 million minimum purchase commitment to avoid contract losses.
- LaserCyte Inventory: Track the realization of the $11.9 million LaserCyte inventory and any potential write-downs if product design changes occur.
- Regulatory Approvals: Monitor the status of the new tilmicosin antibiotic application (expected post-2006) and the expansion of BSE testing programs in the U.S. and EU.